We have developed and studied ~100 different nanoconjugates (polymeric/metallic) for cancer imaging and therapy applications. Uptake by RES and retention in liver is a major drawback. We need to develop new technologies to clear these conjugates out from liver after sufficient time.
Therapeutic compounds (TA) upon entering the systemic circulation undergo various clearance processes, which hinder the activity of the drug by either decreasing the amount of drug that reaches the site of action or by causing toxic side effects in various vital organs. To avoid this and to make sure the TA reaches the target site, a composite system could be composed that protects the TA from the clearance processes ...more »